Validation of Drug Resistance in Pneumonia (DRIP) Score as Empirical Antibiotic Failure Predictor in Community-Acquired Pneumonia Patients in Cipto Mangunkusumo Hospital

Rohayat Bilmahdi Simanjuntak, Khie Chen Lie, Cleopas Martin Rumende, Murdani Abdullah, Hamzah Shatri, Soekamto Koesnoe, Leonard Nainggolan, Aulia Rizka

Abstract


Background: The incidence of CAP due to Drug-Resistant Pathogen (DRP) requires broad-spectrum antibiotic therapy, Drugs Resistance in Pneumonia (DRIP) score can predict these cases. The use of the DRIP score can prevent antibiotic failure and long hospitalization, but validation is needed so that the DRIP score can be used according to the local community at Cipto Mangunkusumo National Central Public Hospital. Methods: This research is a retrospective cohort study in CAP patients who were hospitalized during the period January 2019 to June 2020. Data were taken from medical records. Failure of empiric antibiotics occurs when one of these criteria is found: patient mortality, ICU transfer, and escalation of antibiotics as well as length of stay. Results: 480 patients met the criteria. There were 331 patients (69%) with a DRIP score of <4 and 149 patients (31%) with a DRIP score of≥4. A total of 283 patients (59%) of antibiotic failures were detailed in 174 patients with a DRIP score <4 and 109 patients DRIP score ≥4. DRIP calibration using the Hosmer-Lemeshow test obtained p-value= 0.667 (p>0.05). AUC observations on the ROC curve obtained 0.651 (95% CI; 0.601-0.700). Conclusion: The DRIP score has low accuracy performance and calibration value in predicting empirical antibiotic failure and poor discriminatory value.


Keywords


DRIP score; antibiotics failure; Drug-Resistant Pathogens; Community-Acquired Pneumonia

References


Rider AC, Frazee BW. Community Acquired Pneumonia. Emerg Med Clin Am. 2018;36:665-83.

Rumende CM, Chen LK, Karuniawan A. Hubungan antara ketepatan pemberian antibiotik berdasarkan alur gyssens dengan perbaikan klinis pasien pada pneumonia komunitas. J Penyakit Dalam Indones. 2019;6(2):71.

Rothberg MB. Community-acquired pneumonia. Ann Intern Med. 2022;175(4):ITC49-ITC64.

Lardo S, Chen LK, Santoso WD, Rumende CM. Hubungan kualitas penggunaan antibiotik menggunakan alur gyssens dengan keberhasilan pengobatan pada sepsis MDR gram negatif di rumah sakit tersier. J Penyakit Dalam Indones. 2021;7(4):221.

Cao B, Huang Y, She DY. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J. 2018;12(4):1320-60.

Fadrian F, Chen K, Kumalawati J, Rumende CM, Shatri H, Nelwan EJ. The validation of drug resistance in pneumonia (DRIP) score in predicting infections due to drug-resistant pathogens in community-acquired pneumonia at Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Acta Med Indones. 2021;53(4):416-22.

Webb BJ, Dascomb K, Stenehjem E, Dean N. Predicting risk of drug-resistant organisms in pneumonia: Moving beyond the HCAP model. Respir Med. 2015;109(1):1-10.

Oliver MB, Fong K, Certain L, Spivak ES, Timbrook TT. Validation of a community-acquired pneumonia score to improve empiric antibiotic selection at an academic medical center. Antimicrob Agents Chemother. 2021;65(2):1-7.

Almirall J, Serra-Prat M, Bolíbar I, Balasso V. Risk factors for community-acquired pneumonia in adults: a systematic review of observational studies. Respiration. 2017;94(3):299-311.

Webb BJ, Sorensen J, Mecham I. Antibiotic use and outcomes after implementation of the drug resistance in pneumonia score in ED patients with community-onset pneumonia. Chest. 2019;156(5):843-51.

Garau J, Baquero F, Pérez-Trallero E. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect. 2008;14(4):322-9.


Full Text: PDF

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.